Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-03-08

FDA Approved: LUMIGAN — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Lumigan (bimatoprost) submitted by Allergan, Inc., resulting in an updated label for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lumigan (bimatoprost)

Snippet

SUPPL AP for LUMIGAN (BIMATOPROST)